Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
Authors:
- Yan JiangYJYan Jiang
- Jean-Richard EveillardJEJean-Richard Eveillard
- Marie-Anne CouturierMCMarie-Anne Couturier
- Benoit SoubiseBSBenoit Soubise
- Jian-Min ChenJian-Min Chen
- Sujun GaoSGSujun Gao
- Audrey BasinkoABAudrey Basinko
- Frédéric MorelFMFrédéric Morel
- Nathalie Douet-GuilbertNDNathalie Douet-Guilbert
- Marie-Bérengère TroadecMTMarie-Bérengère Troadec
Open Access
Abstract
This study explores the hypothesis that genetic differences related to an ethnic factor may underlie differences in phenotypic expression of myelodysplastic syndrome (MDS). First, to identify clear ethnic differences, we systematically compared the epidemiology, and the clinical, biological and genetic characteristics of MDS between Asian and Western countries over the last 20 years. Asian MDS cases show a 2- to 4-fold lower incidence and a 10-year younger age of onset compared to the Western cases. A higher proportion of Western MDS patients fall into the very low- and low-risk categories while the intermediate, high and very high-risk groups are more represented in Asian MDS patients according to the Revised International Prognostic Scoring System. Next, we investigated whether differences in prognostic risk scores could find their origin in differential cytogenetic profiles. We found that 5q deletion (del(5q)) aberrations and mutations in TET2, SF3B1, SRSF2 and IDH1/2 are more frequently reported in Western MDS patients while trisomy 8, del(20q), U2AF1 and ETV6 mutations are more frequent in Asian MDS patients. Treatment approaches differ between Western and Asian countries owing to the above discrepancies, but the overall survival rate within each prognostic group is similar for Western and Asian MDS patients. Altogether, our study highlights greater risk MDS in Asians supported by their cytogenetic profile.Keywords
Funding Information
- Ligue Contre le Cancer (comités 22, 29, 35, 56, 79, 41)
- Association Gaétan Saleün (MBT)
- Association Halte au Cancer (MBT)
This publication has 128 references indexed in Scilit:
- The incidence of myelodysplastic syndromes in Western Greece is increasingAnnals of Hematology, 2013
- Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic SyndromesPLOS ONE, 2013
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromesLeukemia, 2013
- Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesisBlood, 2012
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromePLOS ONE, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndromeHaematologica, 2011
- Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemiasBMC Cancer, 2010
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood, 2007